Nuformix plc (LON:NFX – Get Free Report)’s share price rose 4.2% during trading on Wednesday . The stock traded as high as GBX 0.26 and last traded at GBX 0.25. Approximately 17,557,332 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 38,040,898 shares. The stock had previously closed at GBX 0.24.
Nuformix Stock Performance
The firm has a market cap of £5.76 million, a price-to-earnings ratio of -6.95 and a beta of 1.22. The stock’s 50 day simple moving average is GBX 0.26 and its 200-day simple moving average is GBX 0.22.
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings data on Tuesday, January 27th. The company reported GBX (0.04) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Further Reading
- Five stocks we like better than Nuformix
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
